US dealmaking robust despite COVID-19
US M&A activity fell precipitously in the first half of the year but picked up again in H2, especially at the upper end of the market
After the initial shock of the pandemic, M&A activity rebounded significantly in H2. Nevertheless, challenges remain—despite low interest rates and strong stock prices
The past year has been an exceptionally challenging one for societies and economies globally, and many companies were hit hard by COVID-19 lockdowns and travel restrictions.
The huge uncertainty that gripped capital markets early in the pandemic put equities into sharp decline and dealmaking largely on hold as strategic buyers and private equity (PE) firms turned inwards to support existing portfolios. The challenges posed by remote due diligence and uncertainty around valuations provided further reasons for market participants to hold back from transacting.
After this initial period of disruption, however, deal activity rebounded strongly, with total value in H2 significantly higher than the same period in 2019. Buyers assessed COVID-19 business risks, PE owners provided portfolio companies with the necessary support where required and proceeded to look outwards for opportunities to improve companies through acquisitions.
Low interest rates and extensive government support for the economy have helped to revive deal activity. Resilient companies in industries that fared relatively well through lockdowns—such as TMT, food and beverage, and healthcare—have been able to take advantage of high levels of cash and strong stock prices to execute acquisitions.
The rise in deal activity in the second half obscures a bifurcated market, however. Even as activity at the top end of the market exceeded pre-pandemic levels, M&A in the middle-market remained muted, likely due to greater uncertainty around valuations.
Our overall outlook for the next 12 months is cautiously optimistic. A series of successful clinical trials have led to vaccine rollouts, providing a major boost to close the year. And stock markets have looked beyond the pandemic to crest new highs.
A more stable outlook could spark a resurgence of middle-market deals, as well as continue to encourage deal activity among larger firms.
After a difficult period, there is reason for optimism that conditions in 2021 will support the momentum in M&A markets that started to build in the final quarter of 2020.
US M&A activity fell precipitously in the first half of the year but picked up again in H2, especially at the upper end of the market
US buyout activity at the top end of the market dropped significantly but exit value held up in 2020
The TMT sector was buoyed by global spikes in demand as the world shifted toward virtual interactions in every walk of life
Deal activity in the oil & gas sector was severely impacted by the COVID-19 pandemic, as commodities prices plummeted
Businesses and consumers have relied on technology more than ever through the course of the pandemic, supporting strong dealmaking at the top end of the market
M&A value in the healthcare sector (incorporating pharma, medical and biotech) stayed relatively robust in 2020, even without the kind of blockbuster deals the sector had become accustomed to seeing in recent years
Total M&A value in the consumer sector has dropped only 1 percent year-on-year thanks to several significant transactions in the food industry.
Real estate portfolios exposed to hospitality and retail assets have struggled through COVID-19 lockdown periods, but healthcare and logistics investments have performed strongly
2020 saw several decisions from the Delaware courts that will affect M&A dealmaking. We focus on four that may prove especially consequential
The past year has been tumultuous for M&A activity, but with a COVID-19 vaccine rollout underway and pent-up demand among PE firms, the fundamentals are in place for a busy year in 2021
Real estate portfolios exposed to hospitality and retail assets have struggled through COVID-19 lockdown periods, but healthcare and logistics investments have performed strongly
Stay current on global M&A activity
US real estate M&A activity dropped in 2020. With offices, retail and hospitality all under lockdown restrictions, the impact on rent and property values has been severe.
With these core real estate verticals under financial pressure, deal volume in US real estate fell 20 percent to 36 deals for the year. Value over the same period was down 28 percent to US$37 billion. The Dow Jones US Real Estate Index is down 10.5 percent for the year-to-date, even as stocks in other industries have rallied.
Despite these headwinds, certain aspects of the real estate industry— logistics and technology infrastructure among them—have been boosted by the pandemic. This has not yet translated to a large uptick in deal activity, in part, perhaps, due to the difficulty in arriving at a consensus on valuations during this volatile time.
Among the larger deals in tech infrastructure was alternative assets manager Blackstone’s US$350 million sale-and-leaseback deal for 13 industrial sites owned by data storage and information management company Iron Mountain. The shift towards remote work, precipitated by the pandemic, has accelerated the growth in demand for data backup and storage.
The largest transaction of the year saw Blackstone on the sale side and involved another sector that has been boosted heavily by the pandemic: the healthcare sector. The deal saw Blackstone sell BioMed Realty, the largest private owner of life sciences office buildings, to a group of existing BioMed investors in a US$14.6 billion deal to recapitalize the business. The deal represents a sizeable return for Blackstone, which took the asset private in 2015 for US$7.8 billion.
While the retail and hospitality sectors have had an especially tough time throughout the COVID-19 crisis, there has not been the flood of distressed asset M&A that some predicted at the start of the pandemic. As with industries boosted by the health crisis, businesses that have been severely negatively impacted are reluctant to agree to valuations at an uncertain time.
That said, some retail real estate deals have gone ahead. Simon Property Group, for example, made a US$6.2 billion move for shopping mall operator Taubman Centers. Although the outlook for retail space is challenging, retail specialists like Simon have seen opportunities to acquire assets at attractive valuations and build market share.
1. BioMed Realty was acquired by a group of existing BioMed investors for US$14.6 billion
2. Simon Property Group bought Taubman for US$6.2 billion
3. Apartment Investment and Management Co bought Apartment Income REIT Corp for US$5.4 billion
Investors such as Simon and Brookfield Asset Management, which also has an extensive retail real estate portfolio, have turned to M&A to vertically integrate the retail real estate supply chain by investing directly into the retailers that rent spaces in their malls. For instance, Simon and Brookfield have teamed up to buy department store JCPenney, a key mall tenant, out of chapter 11 bankruptcy in a US$1.75 billion deal.
The promise of vaccine rollouts and the beginning of the end of the pandemic in 2021 may bring greater certainty to the real estate market, which could spark a wave of deals.
White & Case means the international legal practice comprising White & Case LLP, a New York State registered limited liability partnership, White & Case LLP, a limited liability partnership incorporated under English law and all other affiliated partnerships, companies and entities.
This article is prepared for the general information of interested persons. It is not, and does not attempt to be, comprehensive in nature. Due to the general nature of its content, it should not be regarded as legal advice.
© 2021 White & Case LLP